Calico

Multiple (cellular senescence, neurodeg.) · ALS, age-related disease

Phase 1Senolytics

Mechanism

Multiple (cellular senescence, neurodeg.)

Intervention class

Small molecule / biologic

Indication

ALS, age-related disease

Stage

Phase 1

Evidence

human

Funding

$2.5B+ Alphabet/AbbVie

Backers

Alphabet, AbbVie

Overview

Alphabet's secretive aging bet. Partnership with AbbVie has pushed several assets into the clinic (e.g. ABBV-CLS-7262 for ALS). Famously opaque on pipeline specifics.

Technology

Calico works in Senolytics — Drugs that hunt down and kill the 'zombie' cells that drive aging.

Read the Senolytics brief →

Related companies

Unity Biotechnology

Bcl-xL inhibition (senolytic)

Insilico Medicine

TNIK inhibition (anti-fibrotic / senescence)

Dorian Therapeutics

USP7 inhibition (senolytic)

Cambrian BioPharma

Multiple (mitophagy, senescence, mTOR)

Company website / source ↗ Open the interactive map →

◢ Boom-cycle briefing

Get ahead of the next biotech boom.

New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.

Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.